• Media Centre
  • Investor relations
  • Client area
  • Client area
  • Stewardship policy
  • Annual reports service

Form of Proxy

ADAPTIVE BIOTECHNOLOGIES CORPORATION

Notes

No. Proposition For Against Abstain
1

Election of Class III Director to serve for a three-year term expiring at the 2028 annual meeting of shareholders: Chad Robins

2

To approve, on a non-binding advisory basis, the compensation of our named executive officers as described in the proxy statement.

3

To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2025.